Metabolon Expands Data Access Strategy to Include TwinsUK Registry
Retrieved on:
Tuesday, June 7, 2022
Imperial College London, TwinsUK, Biomarker, Precision medicine, Adult, King's College London, Research, Urine, Human, Kings, LinkedIn, Ageing, Metabolomics, London, CEO, Partnership, King, Disease, Environment, REF, Blood, Solution, Gene, Cardiovascular disease, Genetic variation, Student, Genetics, ISO, Publication, Lipidomics, Metabolic syndrome, Technology, Health, College and university rankings, COVID-19, Phenotype, Data, Twitter, Diet, CSO, Drug development, University, Pharmaceutical industry, Dietary supplement, Metabolon
MORRISVILLE, N.C., June 7, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, announces a partnership with King's College London to perform metabolomics analysis on TwinsUK registry samples as part of Metabolon's data access strategy. The size and clinical detail of the TwinsUK cohort will allow Metabolon to investigate a broad number of diseases for new relevant biomarkers and support novel therapeutic development for improved patient outcomes.
Key Points:
- The TwinsUK registry is one of the most significant adult twins biospecimens and clinical collections worldwide.
- Through this collaboration, Metabolon will analyze data from global metabolomics and targeted short-chain fatty acid assays on fecal, blood, urine, and saliva samples collected by TwinsUK.
- This will enable Metabolon and TwinsUK to gain insights into the interplay between the gut microbial community and human health.
- Additionally, the partners will examine clinical data and compare previous metabolomics research studies with the TwinsUK dataset.